Merlin expression in secretory meningiomas: Evidence of an NF2-independent pathogenesis? Immunohistochemical study

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 3, 2007, Pages 353-357

  Buccoliero, Anna Maria ^a   Gheri, Chiara Francesca ^a   Castiglione, Francesca ^a   Ammannati, Franco ^b   Gallina, Pasquale ^a   Taddei, Antonio ^a   Garbini, Francesca ^a   Degl'Innocenti, Duccio Rossi ^a   Arganini, Luisa ^a   Di Lorenzo, Nicola ^a   Mennonna, Pasquale ^b   Taddei, Gian Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Immunohistochemistry; Meningioma; Merlin; NF2; Secretory

Indexed keywords

MERLIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MENINGIOMA; NEUROFIBROMATOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEUROFIBROMIN 2;

EID: 34548289473     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213114.27978.3a     Document Type: Article

References (39)

1. Louis DN, Scheithauer BW, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee K, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000.
2. De Vitis LR, Tedde A, Vitelli F, et al. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet. 1996;97:632-637.
3. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841-846.
4. Gutmann DH. The neurofibromatoses: when less is more. Hum Mol Genet. 2001;10:747-755.
5. Perry A, Gutmann DH, Reinfenberger G. Molecular pathogenesis of meningiomas. J Neuro-Oncol. 2004;70:183-202.
6. Perry A, Cai DX, Sheithauer B, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol. 2000;10:872-879.
7. Luis E, Gutman DH. Meningioma: an update. Curr Opin Neurol. 2004;17:687-692.
8. Robb VA, Li W, Gascard P, et al. Identification of a third protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis. 2003;13:191-202.
9. Ueki K, Wen-Bin C, Narita Y, et al. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res. 1999;59:5995-5998.
10. Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000;10:1495-1500.
11. Gutmann DH, Giordano MJ, Fishback AS, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurolol. 1997;49:267-270.
12. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis - the NF2 tumor suppressor, merlin. Genes Dev. 2005; 19:2265-2277.
13. Wellenreuther R, Kraus JA, Lenartz D, et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningiomas. Am J Pathol. 1995;146:827-832.
14. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF-2 associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001;10:994-1003.
15. Caldarella A, Buccoliero AM, Marini M, et al. Oncocytic meningioma: a case report. Pathol Res Pract. 2002;198:109-113.
16. Buccoliero AM, Caldarella A, Taddei A, et al. Atypical, anaplastic and unusual meningiomas. Morphology and incidence in 300 consecutive cases. Pathologica. 2003;95:83-87.
17. Kepes JJ. The fine structure of hyaline inclusions (pseudopsammoma bodies) in meningiomas. J Neuropathol Exp Neurol. 1975;34:282-294.
18. Budka H. Hyaline inclusions (pseudopsammoma bodies) in meningiomas: immunocytochemical demonstration of epithelial-like secretion of secretory component and immunoglobulins A and M. Acta Neuropathol. 1982;56:294-298.
19. Alguacil-Garcia A, Pettigrew NM, Sima AAF. Secretory meningioma. A distinct subtype of meningioma. Am J Surg Pathol. 1986;10:102-111.
20. Ejeckam GC, Azadeh B, Hamad A. Secretory meningioma. Histopathol. 1992;21:475-477.
21. Ide M, Jimbo M, Yamamoto M, et al. MIB-1 staining index and peritumoral brain edema of meningiomas. Cancer. 1996;78:133-143.
22. Probst-Cousin S, Villagran-Lillo R, Lahl R, et al. Secretory meningioma. Clinical histologic, and immunohistochemical findings in 31 cases. Cancer. 1997;79:2003-2015.
23. Çolako∂lu N, Demirtå E, Oktar N, et al. Secretory meningiomas. Report of clinical, immunohistochemical findings in 12 cases and review of literature. J Neuro-Oncol. 2003;62:233-241.
24. Ironside JW, Moss TH, Louis DN, et al. Diagnostic Pathology of Nervous System Tumours. London: Churchill Livingstone; 2002.
25. Wellenreuther R, Waha A, Vogel Y, et al. Quantitative analysis of neurofibromatosis type 2 gene transcript in meningiomas supports the concept of distinct molecular variants. Lab Invest. 1997;6: 601-606.
26. Hitotsumatsu T, Iwaki T, Kitamoto T, et al. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol (Berlin). 1997;93:225-232.
27. Lee JH, Sundaram V, Stein DJ, et al. Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery. 1997;40:578-587.
28. Evans JJ, Jeun SS, Lee JH, et al. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg. 2001;94:111-117.
29. Kalamarides M, Niwa-kawakita M, Leblois H, et al. NF2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in mouse. Gene Dev. 2002;16:1060-1065.
30. Grónholm M, Teesalu T, Tyynelä J, et al. Characterization of the NF2 protein merlin and the ERM protein ezrin in human, rat, and mouse central nervous system. Mol Cell Neurosci. 2005;28:683-693.
31. Rangwala R, Banine F, Borg JP, et al. Erbin regulates mitogen activated protein (MAP) kinase activation and MAP kinase-dependent interactions between merlin and adherens junction protein complexes in schwann cells. J Biol Chem. 2005;280: 11790-11797.
32. James MF, Manchanda N, Gonzalez-Agosti C, et al. The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J. 2001;356:377-386.
33. Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, et al. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol. 1997;56:735-742.
34. James MF, Manchanda N, Gonzalez-Agosti C, et al. The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J. 2001;356:377-386.
35. Chen Y, Gutman DH, Haipek CA, et al. Characterization of chicken NF2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dynam. 2004;229:541-554.
36. Lallemand D, Curto M, Saotome I, et al. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17:1090-1100.
37. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but not other ERM family members in schwannomas. Am J Pathol. 1997;151:1649-1654.
38. Gutmann DH, Geist RT, Xu HM, et al. Defect in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet. 1998;7:335-345.
39. Den Bakker MA, van Tilborg AAG, Kros JM, et al. Truncated NF2 proteins are not detected in meningiomas and schwannomas. Neuropathology. 2001;21:168-173.